On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.
The New York Times reports the Infectious Disease Research Institute in Seattle has laid off about a third of its researchers.
The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.
In PNAS this week: analysis of extensively drug-resistant Mycobacterium tuberculosis strain, regulation of obesity-linked gene, and more.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening.
The project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa starting in October.
In PLOS this week: genes and pathways linked to multiple sclerosis, Salmonella enterica diversity in reptiles, and more.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.